WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis and a major cause of chronic kidney disease and kidney failure worldwide. Recent data on long-term outcomes from a large cohort of patients with IgAN have highlighted that patients with proteinuria <0.88 g/g have high rates of kidney failure within 10 years. This means IgAN cannot be considered benign even when proteinuria is <1 g/day. Early intervention with disease-modifying therapies may be particularly effective early in the natural history of IgAN, before the onset of irreversible kidney fibrosis.